01—Abstract
Summary
Summary of the 8-K filed May 8, 2019. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) has filed an 8-K reporting a significant amendment to its collaboration agreement with Merck Sharp & Dohme Corp. (Merck), effective May 3, 2019.
The key development is the establishment of a new RSV (respiratory syncytial virus) vaccine candidate, mRNA-1172, for which Merck will initiate Phase 1 clinical trials. This amendment reshapes the ongoing collaboration, with Moderna retaining rights for a pediatric RSV vaccine candidate and discontinuing efforts on other viral targets like VZV (varicella zoster virus) with Merck. The filing also includes Moderna's first-quarter 2019 financial results, released on May 8, 2019.
While the details of the financial performance are not elaborated within this 8-K's text, investors should note that this announcement coincides with the material update to the Merck collaboration. The shift in focus for the RSV program and the introduction of a new candidate under the Merck agreement represent a strategic adjustment in Moderna's development pipeline.
02—Key points
Key Highlights
- Moderna subsidiary (ModernaTX, Inc.) entered into a Fifth Amendment to Collaboration and License Agreement with Merck Sharp & Dohme Corp. on May 3, 2019.
- A new development candidate for the prevention of RSV (mRNA-1172) has been established under the amended agreement, with Merck initiating a Phase 1 clinical trial.
- Moderna will have rights to research, develop, and commercialize a development candidate for a specific set of respiratory infections, including RSV, for the pediatric population.
- The collaboration will now focus specifically on RSV, discontinuing efforts on other viruses like VZV (mRNA-1278).
- Development of the previous RSV candidate (mRNA-1777) has been paused, pending results from the new mRNA-1172 Phase 1 trial.
- The 8-K also references the release of Moderna's Q1 2019 financial results on May 8, 2019, via an accompanying press release (Exhibit 99.1).
03—Questions
Frequently Asked Questions
What is the primary change in the collaboration agreement with Merck?
The main change is the introduction of a new RSV vaccine candidate (mRNA-1172) for which Merck will conduct a Phase 1 clinical trial. The collaboration is also narrowing its focus exclusively to RSV and Moderna has secured rights for pediatric applications.
What happens to the previous RSV candidate, mRNA-1777?
The development of mRNA-1777 has been paused. Future steps will depend on the outcomes of the Phase 1 clinical trial for the new candidate, mRNA-1172.
Does Moderna retain any rights related to RSV?
Yes, Moderna has retained the right to research, develop, and commercialize a development candidate for a specific set of respiratory infections, including RSV, targeting the pediatric population.
Are financial details available in this 8-K?
This 8-K filing primarily details the amendment to the Merck collaboration agreement. It references a press release issued on May 8, 2019, for the first-quarter 2019 financial results (Exhibit 99.1), which would contain the specific financial performance data.
04—Continue